These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28477079)

  • 1. [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer].
    Wiggermann P; Brünn K; Bäumler W
    Radiologe; 2017 Aug; 57(8):637-640. PubMed ID: 28477079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.
    Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB
    World J Urol; 2017 Jan; 35(1):11-20. PubMed ID: 27147512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
    Guenther E; Klein N; Zapf S; Weil S; Schlosser C; Rubinsky B; Stehling MK
    PLoS One; 2019; 14(4):e0215093. PubMed ID: 30986263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
    Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
    JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible Electroporation for the Ablation of Prostate Cancer.
    Karagiannis A; Varkarakis J
    Curr Urol Rep; 2019 Sep; 20(10):63. PubMed ID: 31478109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients.
    van den Bos W; de Bruin DM; Jurhill RR; Savci-Heijink CD; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna-Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    World J Urol; 2016 May; 34(5):657-64. PubMed ID: 26296371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
    Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
    Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal Therapy of Prostate Cancer Using Irreversible Electroporation.
    Valerio M; Ahmed HU; Emberton M
    Tech Vasc Interv Radiol; 2015 Sep; 18(3):147-52. PubMed ID: 26365544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
    Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible electroporation: Beyond the limits of tumor ablation.
    Alonso-González R; Abadal Villayandre JM; Gálvez Gonzalez E; Álvarez Perez MJ; Méndez Alonso S; de Gregorio Ariza MA
    Radiologia (Engl Ed); 2024; 66(1):47-56. PubMed ID: 38365354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study.
    van den Bos W; Jurhill RR; de Bruin DM; Savci-Heijink CD; Postema AW; Wagstaff PG; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna Pes MP; de Reijke TM; de la Rosette JJ
    J Urol; 2016 Aug; 196(2):552-9. PubMed ID: 27004693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Developments in Image-Guided Percutaneous Irreversible Electroporation of Solid Tumors.
    Yun JH; Fang A; Khorshidi F; Habibollahi P; Kutsenko O; Etezadi V; Hunt S; Nezami N
    Curr Oncol Rep; 2023 Nov; 25(11):1213-1226. PubMed ID: 37695398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
    BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).
    Valerio M; Dickinson L; Ali A; Ramachandran N; Donaldson I; Freeman A; Ahmed HU; Emberton M
    Contemp Clin Trials; 2014 Sep; 39(1):57-65. PubMed ID: 25072507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
    Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
    Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy.
    Davalos RV; Bhonsle S; Neal RE
    Prostate; 2015 Jul; 75(10):1114-8. PubMed ID: 25809014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.